FDA approves pancreatic cancer drug that extends patients’ lives - The Washington Post

As reported by The Washington Post

In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on The Washington Post ↗

Market Samachar is a news aggregator. This article was originally published by The Washington Post. Tap the button above to read the full story on their site.

INDIAN Gold monetisation: Manappuram, MCX among Jefferies top stock picks Share Market Today
INDIAN Multibagger on listing! Tempsens Instruments shares debut at 111% premium Share Market Today
INDIAN Indices drift higher; market breadth positive Share Market Today
INDIAN Markets not yet pricing in rate hike possibility: Aditya Khemka, InCred Share Market Today
INDIAN Stock Market LIVE: HCLTech, TCS drive 300-pt gain in Sensex; Tejas Networks shares jump 11% Share Market Today
COMPANIES Vodafone Idea shares jump over 120% in one year. Should you buy now or avoid the multibagger? Stocks-Markets-Economic Times
INDIAN Paluck Technologies, Complete Sports, Management SME IPOs open today. Here’s what GMPs indicate Markets-Economic Times
COMPANIES Oil & gas stocks after 6 months of West Asia crisis: Who beat markets, who lagged & what’s next? Stocks-Markets-Economic Times

FDA approves pancreatic cancer drug that extends patients’ lives - The Washington Post

More from Market Samachar